The founding of Johnson & Johnson in 1886 can be traced to a single lecture that most of its audience chose to dismiss as impractical European theorizing. In 1876, at the Philadelphia Centennial Exposition — an extraordinary gathering of world's fair attendees celebrating a century of American independence — the English surgeon Joseph Lister presented his findings on antiseptic surgery to an audience of American physicians and medical students. Lister's central argument was both simple and revolutionary: the infection and death that killed a substantial percentage of surgical patients in the 1870s was not caused by miasma or bad air or constitutional weakness, as most American surgeons believed, but by microscopic organisms — bacteria — that contaminated wounds during and after surgery, and that could be eliminated through systematic application of carbolic acid and other antiseptic agents. Most of the American physicians in the audience were skeptical. One who was not was a thirty-one-year-old man named Robert Wood Johnson, who had been working in the pharmaceutical and surgical supply trade in New York and who recognized in Lister's antiseptic surgery principles an enormous commercial opportunity: if antiseptic methods were going to be adopted in American surgery — and he believed they inevitably would be — then someone needed to manufacture the sterile dressings, sutures, and wound care materials that antiseptic surgery required, in a factory setting that could ensure consistent sterility at scale.
Robert Wood Johnson spent the decade following the Philadelphia Exposition building the practical knowledge and commercial relationships needed to execute on this insight. He worked in the pharmaceutical trade, studying drug manufacturing and distribution, and by the mid-1880s had accumulated sufficient capital and experience to pursue the surgical supply manufacturing business he had envisioned at the world's fair. In 1885 or early 1886 — the precise sequence is subject to some historical ambiguity in the company's records — he invited his two younger brothers to join him in the venture. James Wood Johnson, born in 1851, had developed practical business and commercial skills suitable for managing the operational and financial aspects of a manufacturing enterprise. Edward Mead Johnson, born in 1853, brought both technical and commercial perspective. Together, the three Johnson brothers established their company in New Brunswick, New Jersey — a railroad and river city with good access to raw material suppliers in the mid-Atlantic region and reliable transportation to the hospital and medical supply markets along the Eastern Seaboard.
They began operations in a rented space reported to have previously served as a wallpaper factory, with fewer than fifteen employees producing ready-to-use antiseptic surgical dressings: gauze pads, plasters, and wound care materials sterilized in a factory environment to a standard of cleanliness that no individual hospital dispensary could reliably replicate at the time. The timing proved prescient. American medicine's acceptance of antiseptic surgery principles accelerated through the late 1880s and 1890s, driven by the demonstrably superior outcomes of surgeons who adopted Listerian technique — survival rates that contemporary physicians documented with sufficient clarity to overcome even organized professional skepticism. As antiseptic surgery became standard American practice, demand for factory-produced sterile surgical supplies grew rapidly, and J&J was positioned as one of the few companies prepared to supply them at scale and with consistent quality.
In 1888, J&J published a pamphlet that became a landmark in American medical literature: Modern Methods of Antiseptic Wound Treatment, written in collaboration with physicians and distributed to doctors and hospitals across the country as a practical guide to antiseptic surgical technique. The pamphlet was simultaneously a public health contribution and a commercial marketing document — it taught surgeons how to use antiseptic methods and specifically recommended the sterile dressings and sutures that J&J manufactured. This combination of genuine clinical education and product recommendation established a template for healthcare professional marketing that pharmaceutical and device companies have followed for more than 130 years.
Robert Wood Johnson I died in 1910 and was succeeded by his son Robert Wood Johnson II, known within the company and publicly as The General. Johnson II transformed J&J from a surgical supply manufacturer into the diversified healthcare conglomerate that it would remain for most of the twentieth century — acquiring consumer product businesses, establishing pharmaceutical divisions, and building international operations. Most consequentially for the company's cultural identity, he wrote the J&J Credo in 1943, one year before the company's initial public offering on the New York Stock Exchange. The Credo was an unusual document: a formal articulation of corporate responsibility that placed shareholder interests explicitly in fourth position behind patients, employees, and communities. Johnson II believed that if J&J fulfilled its responsibilities to customers, employees, and communities, shareholders would be rewarded as a consequence — but that shareholder rewards should be the output of responsible behavior, not the primary objective driving it.